These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32545780)

  • 1. Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?
    Charytoniuk T; Zywno H; Konstantynowicz-Nowicka K; Berk K; Bzdega W; Chabowski A
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system in normal and pathological brain ageing.
    Bilkei-Gorzo A
    Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3326-41. PubMed ID: 23108550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoid system in neurodegenerative disorders.
    Basavarajappa BS; Shivakumar M; Joshi V; Subbanna S
    J Neurochem; 2017 Sep; 142(5):624-648. PubMed ID: 28608560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoidome in neuropsychiatry: Opportunities and potential risks.
    Morris G; Walder K; Kloiber S; Amminger P; Berk M; Bortolasci CC; Maes M; Puri BK; Carvalho AF
    Pharmacol Res; 2021 Aug; 170():105729. PubMed ID: 34119623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.
    Jacobson MR; Watts JJ; Boileau I; Tong J; Mizrahi R
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):330-348. PubMed ID: 30635160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An enquiry to the role of CB1 receptors in neurodegeneration.
    Fernández-Moncada I; Eraso-Pichot A; Dalla Tor T; Fortunato-Marsol B; Marsicano G
    Neurobiol Dis; 2023 Aug; 184():106235. PubMed ID: 37481040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
    Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
    Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
    Cristino L; Bisogno T; Di Marzo V
    Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches and current challenges with targeting the endocannabinoid system.
    Morales P; Jagerovic N
    Expert Opin Drug Discov; 2020 Aug; 15(8):917-930. PubMed ID: 32336154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.
    Lowe H; Toyang N; Steele B; Bryant J; Ngwa W
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid system and neurogenesis in health and disease.
    Galve-Roperh I; Aguado T; Palazuelos J; Guzmán M
    Neuroscientist; 2007 Apr; 13(2):109-14. PubMed ID: 17404371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoids in the gastrointestinal tract.
    Lee Y; Jo J; Chung HY; Pothoulakis C; Im E
    Am J Physiol Gastrointest Liver Physiol; 2016 Oct; 311(4):G655-G666. PubMed ID: 27538961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Endocannabinoid System in Epilepsy: For Good or for Bad.
    Martínez-Aguirre C; Cinar R; Rocha L
    Neuroscience; 2022 Feb; 482():172-185. PubMed ID: 34923038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases.
    Kicman A; Pędzińska-Betiuk A; Kozłowska H
    Eur J Pharmacol; 2021 Nov; 911():174560. PubMed ID: 34648805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Cannabinoid System in Alzheimer's Disease.
    Li S; Huang Y; Yu L; Ji X; Wu J
    Curr Neuropharmacol; 2023; 21(3):715-726. PubMed ID: 35105293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endocannabinoid system and multiple sclerosis.
    Baker D; Pryce G
    Curr Pharm Des; 2008; 14(23):2326-36. PubMed ID: 18781983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cannabinoid system and microglia in health and disease.
    Duffy SS; Hayes JP; Fiore NT; Moalem-Taylor G
    Neuropharmacology; 2021 Jun; 190():108555. PubMed ID: 33845074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.
    Paloczi J; Varga ZV; Hasko G; Pacher P
    Antioxid Redox Signal; 2018 Jul; 29(1):75-108. PubMed ID: 28497982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.